Armata Pharmaceuticals, Inc.

ARMP

AMEX

Healthcare

Biotechnology

Marina del Rey, CA, US60 employeesarmatapharma.com

$10.29

-0.28(-2.60%)

Mkt Cap $377M

$0.90

$11.96

52-Week Range

At a Glance

AI-generated

Armata Pharmaceuticals, Inc.

8-K

Armata Pharmaceuticals, Inc. announced a delay in its fourth quarter and full-year 2025 financial results announcement, anticipating filing its Form 10-K on or before March 31, 2026, and provided a corporate update including FDA QIDP designation for AP-SA02, Phase 3 trial plans, cGMP facility commissioning, and positive Phase 2a study results.

$377M

Market Cap

—

Revenue

—

Net Income

Employees60

Fundamentals

How The Business Makes Money

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Industry Biotechnology

Activity

What Changed Recently

Material Agreement

Jan 25, 2026

Entry into a Material Definitive Agreement Amendments to Existing Credit Agreements On January 23, 2026, Armata Pharmaceuticals, Inc. (the “Company”) entered in

Other Event

Apr 1, 2026

| Other Events. | |---|---| Armata Pharmaceuticals, Inc. (“Armata” or the “Company”) has set June 11, 2026 as the date for its 2026 annual meeting of stockholde

Regulation FD

Mar 18, 2026

and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, a

Regulation FD

Feb 22, 2026

and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, a

Regulation FD

Jan 12, 2026

and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, a

Peer Companies

Company	Price	Change	Market Cap	P/E
SLSSELLAS Life Sciences Grou...	$4.12	-2.26%	$586M	-31.2
GNFTGenfit S.A.	$8.95	+4.07%	$446M	-11.6
CCCCC4 Therapeutics, Inc.	$2.81	+4.26%	$233M	-2.0
NVCTNuvectis Pharma, Inc.	$7.57	-0.39%	$201M	-6.8
OABIOmniAb, Inc.	$1.53	-1.60%	$175M	-3.5
CDXSCodexis, Inc.	$1.79	+3.16%	$163M	-3.3
IPHAInnate Pharma S.A.	$1.37	+1.48%	$128M	-2.1
NTHINeonc Technologies Holdin...	$5.96	-2.22%	$119M	-2.9

Analyst View

Company Profile

CIK0000921114

ISINUS04216R1023

CUSIP04216R102

Phone858 829 0829

Address4503 Glencoe Avenue, Marina del Rey, CA, 90292, US

SEC EDGAR